| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
3-Oxo-7-hydroxychol-4-enoic acid targets the bile acid biosynthesis pathway and cholesterol catabolism. As an intermediate in primary bile acid synthesis from cholesterol, it is involved in hepatic lipid metabolism. Its "target" in research is the study of bile acid synthesis disorders, liver function, and metabolic diseases. |
|---|---|
| ln Vitro |
In vitro, 3-Oxo-7-hydroxychol-4-enoic acid is used to study bile acid biosynthesis and cholesterol metabolism. It serves as an intermediate in the sterol biosynthesis pathway. Its activity is studied in cell-free systems and liver cell cultures to investigate the regulation of bile acid synthesis and the effects of inhibitors on sterol metabolism.
|
| ln Vivo |
In vivo, 3-Oxo-7-hydroxychol-4-enoic acid plays a crucial role in the bile acid biosynthesis pathway, contributing to the production of primary bile acids from cholesterol. It is a metabolic product found in human urine. Its levels may serve as a biomarker for hepatobiliary diseases and metabolic disorders.
|
| Enzyme Assay |
In vitro enzyme assays with 3-Oxo-7-hydroxychol-4-enoic acid typically involve studying enzymes of the bile acid biosynthesis pathway such as sterol hydroxylases and oxidoreductases. The compound is used as a substrate or product in assays to characterize enzyme activity. Standard assays involve incubating with enzyme preparations and analyzing products by GC-MS or LC-MS.
|
| Cell Assay |
In vitro cell culture experiments with 3-Oxo-7-hydroxychol-4-enoic acid involve treating hepatocytes or other liver cells to study bile acid biosynthesis and cholesterol metabolism. Cells are treated with the compound or its precursors, and endpoints include assessment of bile acid production, gene expression of enzymes involved in bile acid synthesis, and effects on lipid metabolism.
|
| Animal Protocol |
In vivo animal experiments with 3-Oxo-7-hydroxychol-4-enoic acid typically involve using animal models of hepatobiliary diseases or metabolic disorders. The compound or its precursors are administered to study bile acid biosynthesis and metabolism. Key endpoints include bile acid levels in blood, bile, and tissues, as well as histopathological examination of the liver.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of 3-Oxo-7-hydroxychol-4-enoic acid reflect its role as a metabolic intermediate. It is synthesized in the liver from cholesterol and metabolized to primary bile acids. It is not administered as a drug, and its levels in tissues reflect the activity of the bile acid biosynthesis pathway. It is soluble in DMSO at ≥100 mg/mL.
|
| Toxicity/Toxicokinetics |
3-Oxo-7-hydroxychol-4-enoic acid has a low toxicity profile as a naturally occurring metabolic intermediate. It is not considered a hazardous substance. For research use, standard laboratory safety practices are sufficient. Comprehensive toxicology studies have not been published as the compound is a normal cellular metabolite.
|
| References | |
| Additional Infomation |
7α-Hydroxy-3-oxocholest-4-en-24-acid is a 3-oxoΔ⁴ steroid compound formed by adding a 7α-hydroxy substituent to 3-oxocholest-4-en-24-acid. It is a metabolic product found in human urine. It is a 3-oxoΔ⁴ steroid compound, a 7α-hydroxy steroid compound, a cholestylic acid, and a bile acid. Functionally, it is related to 7α,12α-dihydroxy-3-oxocholest-4-en-24-acid. It is the conjugate acid of 7α-hydroxy-3-oxocholest-4-en-24-acid.
3-Oxo-7-hydroxychol-4-enoic acid is a 3-oxo Δ4-steroid and a bile acid intermediate in the biosynthesis of primary bile acids from cholesterol. It plays a key role in cholesterol catabolism and hepatic lipid metabolism. It is used in studies of bile acid synthesis disorders, liver function, and metabolic diseases. The compound is not a drug and has no therapeutic indications. |
| Molecular Formula |
C24H36O4
|
|---|---|
| Molecular Weight |
388.54
|
| Exact Mass |
388.261
|
| CAS # |
14772-95-3
|
| PubChem CID |
193493
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.606
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
697
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](CC4=CC(=O)CC[C@]34C)O)C
|
| InChi Key |
CFLVYJJIZHNITM-NLXMLWGDSA-N
|
| InChi Code |
InChI=1S/C24H36O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h12,14,17-20,22,26H,4-11,13H2,1-3H3,(H,27,28)/t14-,17-,18+,19+,20-,22+,23+,24-/m1/s1
|
| Chemical Name |
(4R)-4-[(7R,8S,9S,10R,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (257.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5737 mL | 12.8687 mL | 25.7374 mL | |
| 5 mM | 0.5147 mL | 2.5737 mL | 5.1475 mL | |
| 10 mM | 0.2574 mL | 1.2869 mL | 2.5737 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
